HBM7575 / Harbour BioMed, Sichuan Kelun Pharma - LARVOL DELTA

SKB575-I-02: A Randomized, Phase Ib, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SKB575 (HBM7575) in Participants With Asthma (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

A Randomized, Phase Ib, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SKB575 (HBM7575) in Participants With Asthma (clinicaltrials.gov) - P1 | N=36 | Not yet recruiting | Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

New P1 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Harbour BioMed…and Kelun-Biotech …announced that the National Medical Products Administration (NMPA) of China has approved the Investigational New Drug (IND) application for HBM7575/SKB575…for the treatment of asthma. (PRNewswire)

New trial • Asthma

A Study of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis Participants (clinicaltrials.gov) - P1 | N=90 | Recruiting | Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

A Study of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis Participants (clinicaltrials.gov) - P1 | N=90 | Not yet recruiting | Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

New P1 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Harbour BioMed and Kelun-Biotech Announce NMPA Approval of IND Application for HBM7575/SKB575 for the Treatment of Atopic Dermatitis (PRNewswire)

New trial • Atopic Dermatitis